Captrust Financial Advisors Boosts Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Captrust Financial Advisors grew its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 19.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,170 shares of the medical device company’s stock after acquiring an additional 1,647 shares during the period. Captrust Financial Advisors’ holdings in Tandem Diabetes Care were worth $431,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. MN Wealth Advisors LLC increased its position in Tandem Diabetes Care by 3.1% in the second quarter. MN Wealth Advisors LLC now owns 14,723 shares of the medical device company’s stock worth $593,000 after purchasing an additional 440 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of Tandem Diabetes Care by 29.2% in the 2nd quarter. Signaturefd LLC now owns 2,307 shares of the medical device company’s stock valued at $93,000 after buying an additional 522 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Tandem Diabetes Care by 4.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,960 shares of the medical device company’s stock worth $603,000 after purchasing an additional 592 shares during the last quarter. Brooklyn Investment Group acquired a new position in Tandem Diabetes Care during the 3rd quarter valued at about $28,000. Finally, Assetmark Inc. acquired a new stake in Tandem Diabetes Care in the 3rd quarter worth approximately $29,000.

Tandem Diabetes Care Price Performance

NASDAQ TNDM opened at $34.31 on Friday. The business has a 50 day simple moving average of $33.00 and a 200 day simple moving average of $39.82. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of -17.78 and a beta of 1.33. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a 52-week low of $21.85 and a 52-week high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.08. The business had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. Tandem Diabetes Care’s revenue was up 31.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.38) earnings per share. Analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. This trade represents a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

TNDM has been the topic of several analyst reports. Morgan Stanley raised Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price on the stock in a report on Monday, December 2nd. Sanford C. Bernstein assumed coverage on Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Tandem Diabetes Care in a research report on Friday, October 4th. They issued a “neutral” rating and a $46.00 target price for the company. Barclays lifted their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Finally, Citigroup cut their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.81.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.